PFO closure device
DeviceDevice PFO closure.
NCT Number: NCT04946734
Effectivity and safety of PFO closure vs medicine in alleviating migraine (SPRING): a multicenter, random, case control study
This study is active but is not currently recruiting participants.
Notify Me16 year–60 year
All sexes
Interventional
Phase 3
Xiamen Cardiovascular Hospital Xiamen University, Xiamen, Fujian, China
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Device PFO closure.
Aspirin 100mg qd for 6 months and clopidogrel 75mg qd administered for 1month after device implanted.
If migraine recurred, Triptans would be administered during the acute phase.
Time frame: Month 12
Primary Efficacy Endpoint
Time frame: Month 12
Primary Safety Endpoint
Time frame: Baseline and Month 12
Mean change of monthly migraine attacks
Time frame: Baseline and Month 12
Mean change of monthly migraine days. Monthly migraine days = migraine attacks in one month × average time period per attacks (hours) /24 hours
Time frame: Baseline and Month 12
Percentage of subject with at least 50% reduction in monthly migraine attacks from baseline
Guangdong Provincial People's Hospital
Other
Effectivity and Safety of PFO Closure vs Medicine in Alleviating Migraine (SPRING): a Multicenter, Random, Case Control Study
Acronym: SPRING
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05529901
Brain Diseases, Cardiovascular Abnormalities
Okayama, Japan
View Trial DetailsNCT03821129
Brain Diseases, Cardiovascular Abnormalities
Tucson, Arizona, United States
View Trial DetailsNCT07172464
Brain Diseases, Cardiovascular Abnormalities
Los Angeles, California, United States
View Trial DetailsNCT07698951
Brain Diseases, Cardiovascular Abnormalities
Belgrade, Serbia
View Trial Details